Tulane researchers developed a rapid CRISPR-based blood test for Nontuberculous Mycobacteria infections, accurately diagnosing over 93% of cases in two hours.

Tulane University researchers have developed a rapid CRISPR-based blood test that diagnoses Nontuberculous Mycobacteria (NTM) infections in two hours, compared to months with traditional methods. The test, which accurately identifies over 93% of patients with NTM infection, is designed to detect Mycobacterium avium complex (MAC), the most common type and leading cause of NTM-induced pulmonary disease. The test detects NTM DNA fragments in the bloodstream, enabling faster diagnosis and potentially reducing barriers to testing in the face of rising NTM infections.